Catheter Ablation Superior to Drug Therapy for HF
|
By HospiMedica International staff writers Posted on 07 Jan 2019 |
Catheter ablation is superior to conventional drug therapy alone for patients with atrial fibrillation (AF) and heart failure (HF), according to a new study.
Researchers at Mount Sinai Hospital (New York, NY, USA) conducted a meta-analysis of randomized controlled trials extracted from PubMed, the Cochrane Central Register of Controlled Trials, Google Scholar, and other sources in order to compare clinical outcomes of catheter ablation and drug therapy in adults with AF and HF. Six studies involving 775 patients met the inclusion criteria, and an analysis of the studies revealed that compared to medication, catheter ablation was associated with reductions in all-cause mortality and HF hospitalizations.
In addition, compared with drug therapy, AF ablation improved left ventricular ejection fraction (LVEF) six-minute walk test distance, peak oxygen consumption (VO2max), cardiopulmonary exercise capacity, and overall quality of life. Major adverse events rates were 7.2% in the ablation group and 3.8% in the standard therapy group, but were not statistically significant. The study was published on December 25, 2018, in Annals of Internal Medicine.
“Catheter ablation is an established therapeutic strategy for symptomatic, drug-refractory atrial fibrillation. However, current guidelines support atrial fibrillation ablation with caution,” concluded lead author Mohit Turagam, MD, and colleagues. “The long-term benefits in all-cause mortality, heart failure hospitalizations, and overall clinical outcomes must be weighed in clinical decision making, despite the complications.”
Cardiac catheter ablation is used to treat a variety of cardiac arrhythmias, especially supraventricular tachyarrhythmias such as AF, atrial flutter, and atrial tachycardia. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue to prevent the spread of electrical signals; the procedure is low-risk, usually takes 2-4 hours, and is performed in an electrophysiology or a cardiac catheterization lab. It is successful in about 90% of the people who have it.
Related Links:
Mount Sinai Hospital
Researchers at Mount Sinai Hospital (New York, NY, USA) conducted a meta-analysis of randomized controlled trials extracted from PubMed, the Cochrane Central Register of Controlled Trials, Google Scholar, and other sources in order to compare clinical outcomes of catheter ablation and drug therapy in adults with AF and HF. Six studies involving 775 patients met the inclusion criteria, and an analysis of the studies revealed that compared to medication, catheter ablation was associated with reductions in all-cause mortality and HF hospitalizations.
In addition, compared with drug therapy, AF ablation improved left ventricular ejection fraction (LVEF) six-minute walk test distance, peak oxygen consumption (VO2max), cardiopulmonary exercise capacity, and overall quality of life. Major adverse events rates were 7.2% in the ablation group and 3.8% in the standard therapy group, but were not statistically significant. The study was published on December 25, 2018, in Annals of Internal Medicine.
“Catheter ablation is an established therapeutic strategy for symptomatic, drug-refractory atrial fibrillation. However, current guidelines support atrial fibrillation ablation with caution,” concluded lead author Mohit Turagam, MD, and colleagues. “The long-term benefits in all-cause mortality, heart failure hospitalizations, and overall clinical outcomes must be weighed in clinical decision making, despite the complications.”
Cardiac catheter ablation is used to treat a variety of cardiac arrhythmias, especially supraventricular tachyarrhythmias such as AF, atrial flutter, and atrial tachycardia. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue to prevent the spread of electrical signals; the procedure is low-risk, usually takes 2-4 hours, and is performed in an electrophysiology or a cardiac catheterization lab. It is successful in about 90% of the people who have it.
Related Links:
Mount Sinai Hospital
Latest Critical Care News
- Personalized Brain “Pacemakers” Could Help Patients with Hard-To-Treat Epilepsy
- Microscopic DNA Flower Robots to Enable Precision Medicine Delivery
- Origami Robots to Deliver Medicine Less Invasively and More Effectively
- Improved Cough-Detection Technology Aids Health Monitoring
- AI Identifies Children in ER Likely to Develop Sepsis Within 48 Hours
- New Radiofrequency Therapy Slows Glioblastoma Growth
- Battery-Free Wireless Multi-Sensing Platform Revolutionizes Pressure Injury Detection
- Multimodal AI to Revolutionize Cardiovascular Disease Diagnosis and Treatment
- AI System Reveals Hidden Diagnostic Patterns in Electronic Health Records
- Highly Sensitive On-Skin Sensing Monitor Detects Vitamin B6 and Glucose in Sweat
- Artificial Intelligence Revolutionizing Pediatric Anesthesia Management
- New Device Detects Tuberculosis DNA Directly in Exhaled Air
- New Menstrual Cup Could Detect Infections and Improve Diagnostics
- Engineered “Natural Killer” Cells Could Help Fight Cancer
- Faster Lymph Flow Predicts Better Response to Diuretics in Acute Heart Failure
- New Global Recommendations Aim to End Deaths from Postpartum Hemorrhage
Channels
Surgical Techniques
view channel
Novel Glue Prevents Complications After Breast Cancer Surgery
Seroma and prolonged lymphorrhea are among the most common complications following axillary lymphadenectomy in breast cancer patients. These postoperative issues can delay recovery and postpone the start... Read more
Breakthrough Brain Implant Enables Safer and More Precise Drug Delivery
Delivering medication directly to specific regions of the brain has long been a major challenge in treating neurological disorders. Current implants and infusion systems typically reach only one or two... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more







